Redwood City, Calif., May 6, 2026
Revolution Medicines, Inc. announced the publication of important Phase 1/2 clinical trial data for daraxonrasib (RMC-6236) in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) in the prestigious New England Journal of Medicine (NEJM). The published findings provide strong scientific validation for the company’s global Phase 3 registrational study, RASolute 302, which recently reported positive topline results demonstrating an unprecedented overall survival benefit compared with standard chemotherapy in previously treated metastatic pancreatic cancer patients. The data further strengthen growing industry confidence in next-generation RAS(ON) inhibitors, a new class of targeted oncology therapies designed to directly inhibit one of the most difficult cancer-driving pathways in solid tumors. Revolution Medicines believes daraxonrasib has the potential to become a transformative targeted treatment option for patients suffering from aggressive RAS-mutated cancers, particularly pancreatic cancer where survival outcomes remain extremely poor despite decades of chemotherapy-based treatment approaches.
Phase 1/2 Data Show Promising Activity in RAS-Mutant PDAC
The Phase 1/2 data published in NEJM were generated from the ongoing RMC-6236-001 clinical trial, an open-label multicenter study evaluating daraxonrasib monotherapy in patients with previously treated metastatic solid tumors harboring RAS mutations. In the pancreatic cancer cohort, daraxonrasib demonstrated encouraging anti-tumor activity, durable clinical responses, and a manageable safety profile in heavily pretreated metastatic PDAC patients.
According to Revolution Medicines, the findings provided critical clinical insights that directly supported the launch of the pivotal RASolute 302 Phase 3 trial, which later showed significant overall survival improvement versus standard cytotoxic chemotherapy. Pancreatic ductal adenocarcinoma represents one of the deadliest forms of cancer globally, with more than 90% of patients harboring RAS mutations, making the disease highly dependent on abnormal RAS signaling pathways for tumor growth and survival.
Because existing therapies largely rely on non-targeted chemotherapy regimens with limited effectiveness, the emergence of broad-spectrum RAS-targeted therapies like daraxonrasib is viewed as a potentially major breakthrough in oncology drug development. Company executives emphasized that the consistency between the Phase 1/2 observations and the later positive Phase 3 survival outcomes reinforces confidence in daraxonrasib’s clinical utility across multiple RAS-driven cancers.
Advertisement
Daraxonrasib Expands Leadership in the RAS Oncology Space
Daraxonrasib is an investigational oral RAS(ON) multi-selective inhibitor designed to suppress signaling across a broad range of RAS mutations rather than targeting only a single mutation subtype. The drug works by blocking interactions between activated wild-type and mutant RAS proteins and their downstream effectors, effectively shutting down cancer-driving cellular pathways.
The therapy has already received significant regulatory support from the U.S. Food and Drug Administration, including Breakthrough Therapy Designation, Orphan Drug Designation, and selection for the FDA Commissioner’s National Priority Voucher pilot program, which aims to accelerate development timelines for high-priority therapies addressing major unmet medical needs.
In addition to pancreatic cancer, Revolution Medicines is actively evaluating daraxonrasib in several other Phase 3 registrational trials involving metastatic non-small cell lung cancer (NSCLC) and additional RAS-mutant solid tumors. Industry analysts increasingly view broad RAS inhibition as one of the most important frontiers in precision oncology due to the prevalence of RAS mutations across multiple difficult-to-treat cancers. Revolution Medicines’ expanding RAS(ON) pipeline also includes mutation-selective inhibitors targeting G12C, G12D, G12V, Q61H, and G13C mutations, positioning the company among the leading innovators in targeted RAS oncology therapeutics.
Pancreatic Cancer Remains a Massive Unmet Medical Need
Pancreatic cancer continues to represent one of the highest unmet needs in global oncology, with approximately 60,000 new cases diagnosed annually in the United States and nearly 50,000 deaths each year. Most patients are diagnosed at advanced metastatic stages due to the absence of early symptoms and effective screening methods, resulting in extremely poor long-term survival rates.
Metastatic PDAC currently carries an estimated five-year survival rate of only about 3%, highlighting the urgent demand for innovative targeted treatment options capable of improving outcomes beyond conventional chemotherapy. The publication of daraxonrasib data in NEJM significantly elevates the visibility of Revolution Medicines’ clinical program while also validating the broader therapeutic strategy of targeting activated RAS signaling directly. If ongoing registrational studies continue producing positive survival outcomes, daraxonrasib could emerge as a major new standard-of-care option for patients with RAS-addicted cancers worldwide.
Source: Revolution Medicines press release
